SARS2

Across TCGA pan-cancer cohorts, SARS2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SARS2 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SARS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SARS2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where SARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.691	0.443	.004	21	view →
HNSC	DFS	Median	All	0.854	0.350	.022	7	view →
LUAD	DFS	Median	All	0.449	0.735	.010	6	view →
CCRCC	DFS	Quartile	II,III,IV	0.380	0.763	.023	4	view →
UCEC	OS	Median	All	0.852	0.967	.028	4	view →
GBM	OS	Tertile	All	0.861	0.765	.042	3	view →
LSCC	DFS	Median	II,III,IV	1.000	0.841	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SARS2–PDAC (OS)

Open the PDAC breakdown →